RKIP and MAP Kinase Pathway in Merkel Cell Carcinoma
Author Information
Author(s): Roland Houben, Sonja Ortmann, Juergen C Becker
Primary Institution: Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie, Julius-Maximilians-Universität, Würzburg, Germany
Hypothesis
RKIP might be causative for MAP kinase pathway silencing in Merkel cell carcinoma.
Conclusion
RKIP expression is not critical for the inactivity of the MAP kinase pathway, proliferation properties, and sensitivity of MCC cells towards apoptosis-inducing agents.
Supporting Evidence
- RKIP knock down did not induce any detectable phosphorylation of ERK.
- Proliferation and chemosensitivity towards cisplatin were not altered upon knock down of RKIP.
- The absence of phosphorylation of the MAP kinases ERK1 and ERK2 was not affected by RKIP knock down.
Takeaway
The study found that a protein called RKIP doesn't help turn on a pathway that helps cells grow in a type of skin cancer called Merkel cell carcinoma.
Methodology
RKIP expression was knocked down in UISO cells using siRNA, and the effects on MAP kinase pathway activity, proliferation, and chemosensitivity were assessed.
Participant Demographics
The MCC cell line UISO was established from a primary Merkel cell carcinoma of a 46-year-old woman.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website